🐂 Not all bull runs are created equal. November’s AI picks include 5 stocks up +20% eachUnlock Stocks

Vaxcyte shares hold Buy rating on positive ACIP feedback

EditorNatashya Angelica
Published 07/01/2024, 11:09 AM
PCVX
-

On Monday, Vaxcyte, Inc. shares (NASDAQ:PCVX) maintained its Buy rating from TD Cowen, bolstered by positive comments from the Advisory Committee on Immunization Practices (ACIP). The committee's enthusiasm for modifying age-based recommendations for pneumococcal conjugate vaccines (PCVs) to expand coverage aligns with the potential of Vaxcyte's VAX-24/31.

The analyst from TD Cowen expressed confidence in VAX-24/31 meeting the ACIP's criteria for a broader vaccine recommendation. A decision from the ACIP is anticipated to occur either in October or more likely in February, following the expected release of VAX-13 data in the third quarter, which is predicted to meet current expectations.

The timing of the ACIP's vote is significant as it could coincide closely with the approval of VAX-24/31. The vaccine aims to address the needs of the population aged 50 and above, and a delay in the committee's decision could benefit Vaxcyte if it aligns with the vaccine's approval timeline.

The positive outlook from TD Cowen reflects a belief in Vaxcyte's ability to fulfill the ACIP's desire for a PCV that provides wider protection. The committee's vote, whether in October or February, will be a critical milestone for the company as it seeks to bring VAX-24/31 to market.

The reaffirmation of the Buy rating for Vaxcyte underscores the potential impact of VAX-24/31 on the pneumococcal vaccine landscape. The company's progress and the forthcoming ACIP decision remain focal points for investors monitoring Vaxcyte's trajectory in the vaccine industry.

In other recent news, Cathie Wood's ARK ETF has made several noteworthy transactions. Earnings and revenue results indicate a significant purchase of PagerDuty (NYSE:PD) Inc shares, valued at $1,623,106.

ARK also bought shares of Roblox Corp and Veracyte (NASDAQ:VCYT) Inc, worth $634,668 and $915,397 respectively, while offloading shares in Teladoc (NYSE:TDOC) Health Inc, Verve Therapeutics Inc, and Zoom Video Communications (NASDAQ:ZM) Inc.

In addition, ARK has increased its investment in Markforged Holding Corp, buying shares worth $38,127. These transactions reflect recent developments in ARK's investment strategy. However, it's important to note that these are not predictions of the company's future financial health, but rather facts based on recent actions by ARK ETF.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.